Journal For Clinical Studies
Journal For Clinical Studies

SEARCH

MEDIA PACK
NEWS

MENU

Current Edition

 
FDA

Novartis keeps the leukemia innovation coming with FDA approval for Gleevec follow-on Scemblix as Tasigna patent cliff nears

About two decades ago, Novartis transformed leukemia treatment with the introduction of Gleevec. Now, the Swiss pharma has ushered a third-generation therapy targeted against the …

2 November 2021 Regional News FDA Gleevec
Continue Reading →
 
jcs-white

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Twitter Linkedin
Journal For Clinical Studies © 2022, All Rights Reserved – Powered by Teksyte